Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data

References

• CliftonGT, HaleD, VreelandTJ. et al. Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab vs trastuzumab to prevent recurrences in high-risk HER2 low-expressing breast cancer patients. Clin Cancer Res. 2020:clincanres.2741.2019. doi:10.1158/1078-0432.CCR-19-2741
   Web of Science ®Google Scholar
• CliftonGT, PeoplesGE, MittendorfEA. The development and use of the E75 (HER2 369-377) peptide vaccine. Future Oncol. 2016;12(11):1321–1329. doi:10.2217/fon-2015-005427044454
   PubMed Web of Science ®Google Scholar
• MittendorfEA, LuB, MeliskoM, et al. Efficacy and safety analysis of Nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial. Clin Cancer Res. 2019;25(14):4248–4254. doi:10.1158/1078-0432.CCR-18-286731036542
   PubMed Web of Science ®Google Scholar
• FiskB, BlevinsTL, WhartonJT, IoannidesCG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med. 1995;181(6):2109–2117. doi:10.1084/jem.181.6.21097539040
   PubMed Web of Science ®Google Scholar
• BenavidesLC, GatesJD, CarmichaelMG, et al. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res. 2009;15(8):2895–2904. doi:10.1158/1078-0432.CCR-08-112619351776
   PubMed Web of Science ®Google Scholar
• FiskB, SavaryC, HudsonJM, et al. Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction. J Immunother Emphasis Tumor Immunol. 1995;18(4):197–209. doi:10.1097/00002371-199511000-000018680648
   PubMed Web of Science ®Google Scholar
• AminA, BenavidesLC, HolmesJP, et al. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol Immunother. 2008;57(12):1817–1825. doi:10.1007/s00262-008-0509-218392824
   PubMed Web of Science ®Google Scholar
• BrossartP, StuhlerG, FladT, et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 1998;58(4):732–736.9485028
   PubMed Web of Science ®Google Scholar
• HolmesJP, CliftonGT, PatilR, et al. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2011;117(3):463–471. doi:10.1002/cncr.2558620845479
   PubMed Web of Science ®Google Scholar
• KawashimaI, HudsonSJ, TsaiV, et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol. 1998;59(1):1–14. doi:10.1016/S0198-8859(97)00255-3
   PubMed Web of Science ®Google Scholar
• KonoK, TakahashiA, SugaiH, et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res. 2002;8(11):3394–3400.12429626
   PubMed Web of Science ®Google Scholar
• LustgartenJ, TheobaldM, LabadieC, et al. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. Hum Immunol. 1997;52(2):109–118. doi:10.1016/S0198-8859(96)00292-39077559
   PubMed Web of Science ®Google Scholar
• KuererHM, PeoplesGE, SahinAA, et al. Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast. J Interferon Cytokine Res. 2002;22(5):583–592. doi:10.1089/1079990025298206112060497
   PubMed Web of Science ®Google Scholar
• BrossartP, WirthsS, StuhlerG, ReichardtVL, KanzL, BruggerW. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000;96(9):3102–3108. doi:10.1182/blood.V96.9.310211049990
   PubMed Web of Science ®Google Scholar
• ZaksTZ, RosenbergSA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res. 1998;58(21):4902–4908.9809997
   PubMed Web of Science ®Google Scholar
• KnutsonKL, SchiffmanK, CheeverMA, DisisML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res. 2002;8(5):1014–1018.
   PubMed Web of Science ®Google Scholar
• MurrayJL, GilloglyME, PrzepiorkaD, et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2002;8(11):3407–3418.12429628
   PubMed Web of Science ®Google Scholar
• MittendorfEA, CliftonGT, HolmesJP, et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014;25(9):1735–1742. doi:10.1093/annonc/mdu21124907636
   PubMed Web of Science ®Google Scholar
• PeoplesGE, GurneyJM, HuemanMT, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J clin oncol. 2005;23(30):7536–7545. doi:10.1200/JCO.2005.03.04716157940
   PubMed Web of Science ®Google Scholar
• PeoplesGE, HolmesJP, HuemanMT, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res. 2008;14(3):797–803. doi:10.1158/1078-0432.CCR-07-144818245541
   PubMed Web of Science ®Google Scholar
• MittendorfEA, CliftonGT, HolmesJP, et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2012;118(10):2594–2602. doi:10.1002/cncr.2657421989902
   PubMed Web of Science ®Google Scholar
• PeaceKM, LittonJK, MurthyRK, et al. Pre-specified interim analysis in a prospective, randomized phase II trial of trastuzumab vs trastuzumab + NeuVax to prevent breast cancer recurrence in HER2+ breast cancer patients. Paper presented at: American Association of Cancer Researchers, Annual Meeting; 2017; Washington, DC.
   Google Scholar
• Mittendorf ElizabethA, PlitasG, GarberJ, et al. Abstract OT3-01-04: VADIS trial: phase II trial of the nelipepimut-S peptide vaccine in women with DCIS of the breast. Paper presented at: San Antonio Breast Cancer Symposium; 2016; San Antonio, TX.
   Google Scholar
• LowenfeldL, MickR, DattaJ, et al. Dendritic cell vaccination enhances immune responses and induces regression of HER2(pos) DCIS independent of route: results of randomized selection design trial. Clin Cancer Res. 2017;23(12):2961–2971. doi:10.1158/1078-0432.CCR-16-192427965306
   PubMed Web of Science ®Google Scholar
• ArabA, BehravanJ, RazazanA, et al. A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice. J Drug Target. 2018;26(4):365–372. doi:10.1080/1061186X.2017.138778828972792
   PubMed Web of Science ®Google Scholar
• SerodyJ; 2020 Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT00266110. Accessed 311, 2020.
   Google Scholar
• Chianese-BullockKA, IrvinWPJr., PetroniGR, et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother. 2008;31(4):420–430. doi:10.1097/CJI.0b013e31816dad1018391753
   PubMed Web of Science ®Google Scholar
• DillonPM, PetroniGR, SmolkinME, et al. A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer. J Immunother Cancer. 2017;5(1):92. doi:10.1186/s40425-017-0295-529157306
   PubMed Web of Science ®Google Scholar
• ChamaniR, RanjiP, HadjiM, NahvijouA, EsmatiE, AlizadehAM. Application of E75 peptide vaccine in breast cancer patients: a systematic review and meta-analysis. Eur J Pharmacol. 2018;831:87–93. doi:10.1016/j.ejphar.2018.05.01029753042
   PubMed Web of Science ®Google Scholar